10-Q: Solsence Q3 Loss Amid Revenue Dip, Strategic Shift to Consumer Products

Solsence, Inc. reported a net loss in Q3 2025 despite nine-month revenue growth, as the company continues its strategic pivot towards consumer products.

Summary

• Solsence, Inc. (formerly Nanophase Technologies Corporation) rebranded and uplisted to Nasdaq under the symbol SLSN on April 8, 2025.
• Total revenue for the three months ended September 30, 2025, decreased to $14,597 thousand from $16,866 thousand in the prior year period.
• Total revenue for the nine months ended September 30, 2025, increased to $49,581 thousand from $39,780 thousand in the prior year period.
• The company reported a net loss of $(1,120) thousand for the three months ended September 30, 2025, compared to net income of $3,045 thousand in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $1,627 thousand, down from $4,793 thousand in the prior year period.
• Basic net loss per share for Q3 2025 was $(0.02), compared to basic net income per share of $0.04 in Q3 2024.
• Basic net income per share for the nine months ended September 30, 2025, was $0.02, down from $0.08 in the prior year period.
• Cash at the end of the period (September 30, 2025) was $429 thousand, a significant decrease from $1,409 thousand at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(10,386) thousand, compared to $(218) thousand in the prior year period.
• The company received an Employee Retention Credit (ERC) payment of $1,729 thousand, plus $272 thousand in interest, in June 2025, recognizing $1,234 thousand as other income and $194 thousand as interest income, with a $572 thousand reserve for potential IRS audit discrepancy.
• A settlement agreement was reached with Solarium Brands, LLC and A-Frame Brands, LLC, resulting in a one-time payment of $675,000 to Solsence by January 15, 2026.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the company achieved significant nine-month revenue growth and made strategic moves like rebranding and Nasdaq uplisting, the Q3 net loss, declining gross profit, and substantial increase in cash used in operating activities are significant concerns. The reliance on increased debt for liquidity and high customer concentration also weigh on the sentiment, despite the positive legal settlement and ERC payment.

Positives

• Nine-month total revenue increased significantly to $49,581 thousand in 2025 from $39,780 thousand in 2024, driven by higher sales in consumer products.
• Successful rebranding to Solsence, Inc. and uplisting to Nasdaq under SLSN, enhancing market visibility and access to capital.
• Strategic focus on high-growth consumer products (skin health, sun care, color cosmetics) is driving increased sales in this category.
• Resolution of the Employee Retention Credit (ERC) contingency resulted in a cash payment of $1,729 thousand and $272 thousand in interest, with $1,234 thousand recognized as other income.
• Settlement of legal disputes with Solarium Brands, LLC and A-Frame Brands, LLC will result in a $675,000 payment to Solsence by January 15, 2026.
• Increased borrowing capacity on the A/R Revolver Facility to $12,000 thousand and Inventory Revolver Facility to $10,000 thousand, with maturities extended to April 30, 2027, providing enhanced liquidity.
• Total stockholders' equity increased to $17,227 thousand as of September 30, 2025, from $14,946 thousand at December 31, 2024.

Negatives

• Net loss of $(1,120) thousand for the three months ended September 30, 2025, compared to net income of $3,045 thousand in the prior year period.
• Total revenue decreased for the three months ended September 30, 2025, to $14,597 thousand from $16,866 thousand, primarily due to lower sales in personal care ingredients and advanced materials.
• Gross profit decreased for both the three-month period ($3,370 thousand vs. $6,102 thousand) and nine-month period ($12,629 thousand vs. $13,422 thousand) compared to the prior year.
• Net cash used in operating activities significantly increased to $(10,386) thousand for the nine months ended September 30, 2025, from $(218) thousand in the prior year, primarily due to increased accounts receivable and decreased accounts payable and deferred revenue.
• Cash balance significantly declined to $429 thousand at September 30, 2025, from $1,409 thousand at December 31, 2024.
• Selling, general and administrative expense increased substantially due to higher legal costs, increased allowance for credit loss, increased employee-related costs, severance costs, and uplisting costs.
• High customer concentration, with three significant customers accounting for 60% of total revenue in Q3 2025 and 55% for the nine months ended September 30, 2025.
• Manufacturing operating inefficiencies and facilities improvements contributed to increased cost of revenue for both the threeand nine-month periods.

Risks

• Ability to achieve consistent profitability despite historical losses.
• Dependence on a limited number of key customers, with potential for purchase order or supply agreement cancellations.
• Contingencies in supply agreements with BASF Corporation that could trigger a requirement to sell production equipment, leading to a significant loss of revenue.
• Potential inability to obtain working capital on acceptable terms or at all.
• Challenges in obtaining materials (e.g., Rare Earth elements, high purity zinc) at costs that can be passed through to customers.
• Uncertain demand for Solsence products and advanced materials.
• Limitations in manufacturing capacity and product mix flexibility in response to customer demand.
• Limited marketing experience, particularly with the suite of Solsence consumer products.
• Changes in development and distribution relationships.
• Impact of competitive products and technologies.
• Dependence on patents and the ability to protect proprietary information.
• Ability to maintain an appropriate electronic trading venue for securities.
• Impact of potential new governmental regulations, especially those focusing on nanomaterials, which could be difficult or costly to comply with.
• Business interruptions due to unexpected events or public health crises.
• Resolution of litigation or other legal proceedings.

Future Outlook

The company expects capital spending for currently known needs in 2025 to be between $0.1 million and $1 million, funded by profit from operations, existing loans, lines of credit, and possible new debt financing. Capital expenditures may fall below this range if projects are delayed or unsuccessful, or exceed it with substantial success in business development. The strategic focus is on expanding efforts in consumer products where innovation and growth have been proven, while advanced materials will make up less of the total business over time. Management anticipates that increased product revenue volume will lead to more efficient absorption of fixed manufacturing costs and increased margins. The most critical operational issue is reducing controllable variable product manufacturing costs.

Management Comments

• Management believes that growth in consumer products is happening now due to a confluence of our technology and market conditions that favor the types of products we produce.
• We continue to see unprecedented demand for these products.
• Coupled with our expanded and growing expertise in these areas, we believe we are well positioned to enjoy growth into the future.
• While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus, and we expect it to make up less of our total business over time.
• We may develop additional technologies or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.
• Our most critical operational issue today is reducing controllable variable product manufacturing costs.

Industry Context

Solsence operates in the beauty and life-science markets, with a primary focus on skin health through consumer products and Active Pharmaceutical Ingredients (APIs). The company's strategic pivot towards consumer products aligns with growing consumer demands for 'clean and inclusive beauty' and leverages its proprietary technology platform. While demand for medical diagnostics ingredients has decreased, the company is capitalizing on its expertise in materials engineering for skin health applications. The industry is characterized by evolving consumer preferences and the need for continuous innovation in product formulations and technologies.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for industry standard assessment.

Legal Proceedings

• On October 31, 2025, Solsence, Inc. and Solsence, LLC entered into a Confidential Settlement Agreement and Release with Solarium Brands, LLC and A-Frame Brands, LLC to settle disputes regarding consumer personal care products.
• Solarium agreed to pay Solsence a one-time settlement payment of $675,000 on or before January 15, 2026.

Related Party Transactions

• Lines of credit and term loans are maintained with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, a majority common stock owner and brother of Ms. R. Janet Whitmore, a director and chair of the board.
• Related party interest expense for the three months ended September 30, 2025, was $338 thousand, compared to $152 thousand in 2024.
• Related party interest expense for the nine months ended September 30, 2025, was $795 thousand, compared to $546 thousand in 2024.
• Outstanding balances with Beachcorp, LLC were $14,816 thousand as of September 30, 2025, up from $4,000 thousand at December 31, 2024.
• Outstanding balances with Strandler, LLC were $1,000 thousand as of September 30, 2025, consistent with December 31, 2024.

Stakeholder Impact

• **Shareholders**: Experienced a net loss in Q3 2025 and reduced net income for the nine-month period, leading to a decrease in basic EPS. The strategic shift to consumer products and Nasdaq uplisting could offer long-term growth potential, but current operational cash burn and reliance on debt are concerns.
• **Employees**: Increased salary and benefit costs, along with severance costs, indicate ongoing adjustments in employee-related expenses. The focus on expanding manufacturing capabilities may lead to future job opportunities.
• **Customers**: High customer concentration means a few customers significantly influence revenue. The company's focus on 'clean and inclusive beauty' products aims to meet evolving consumer demands. The BASF agreement poses a risk of equipment sale and revenue loss if performance requirements are not met.
• **Creditors**: Related party lenders (Beachcorp, LLC and Strandler, LLC) have extended significant credit and increased borrowing limits, indicating continued support but also increased leverage for the company. The credit facility with Libertyville Bank & Trust has superior collateral rights.
• **Suppliers**: The company faces risks related to obtaining materials at costs that can be passed through to customers, particularly for Rare Earth elements and high purity zinc, which could impact supplier relationships and costs.

Next Steps

• Continue to expand efforts in consumer products, leveraging proven innovation and growth.
• Focus on reducing controllable variable product manufacturing costs to improve margins.
• Monitor and adjust pricing strategies to pass through raw material cost increases to customers.
• Increase throughput and cost efficiency in manufacturing to achieve greater scale.
• Potentially seek new debt financing to fund capital requirements for growth initiatives.
• Await $675,000 settlement payment from Solarium Brands, LLC by January 15, 2026.

Key Dates

Recommendation

Solsence, Inc. presents a mixed financial picture. While the nine-month revenue growth and strategic pivot to high-demand consumer products are positive long-term indicators, the significant net loss in Q3 2025, declining gross profit margins, and substantial increase in cash used in operating activities raise immediate concerns about profitability and liquidity. The company's reliance on related-party debt for financing, coupled with high customer concentration and potential risks from the BASF agreement, suggests a cautious approach. The recent Nasdaq uplisting and legal settlement are favorable, but the underlying operational challenges need to be addressed for sustained financial health. A 'hold' recommendation is appropriate as investors should monitor the company's ability to improve profitability, manage operating cash flow, and successfully execute its strategic shift in the coming quarters before considering further investment.

Keywords

Solsence, Nanophase Technologies, 10-Q, Quarterly Report, Financial Results, Consumer Products, Skin Health, Personal Care Ingredients, Advanced Materials, Nasdaq Uplisting, SEC Filing, Financial Performance, Revenue, Net Loss, Cash Flow, Related Party Debt, Employee Retention Credit, Legal Settlement